JP Morgan analyst Ken Goldman maintains Conagra Brands (NYSE:CAG) with a Neutral and raises the price target from $38 to $43.
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.